Home > Oncology > ASCO 2019 > Gastrointestinal Cancers > Maintenance olaparib improved PFS in patients with BRCA+ pancreatic cancer

Maintenance olaparib improved PFS in patients with BRCA+ pancreatic cancer

Presented By
Dr Hedy L. Kindler, The University of Chicago, USA
Conference
ASCO 2019
Trial
Phase 3, POLO
  Medical writer: Tim Donald, ELS Maintenance therapy with olaparib prolonged progression-free survival (PFS) of metastatic pancreatic cancer (MPC) with a germline BRCA mutation in the randomized, phase III POLO trial. Olaparib, which was administered following first-line treatment with platinum-based chemotherapy, was well tolerated, and health-related quality of life (HRQOL) was preserved compared with placebo. Hedy L. Kindler, MD, FASCO, of The University of Chicago, presented these results (Abstract LBA4) during the June 2 Plenary Session. “Our results are the first from a phase III trial to validate a targeted treatment in a biomarker-selected population of patients with pancreatic cancer, highlighting the importance of germline BRCA mutation testing in this setting,” Dr. Kindler said. “We conclude that a strategic approach of first-line platinum-based chemotherapy followed by olaparib treatment should become a new standar...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on